Abstract | Transforming growth factor-β (TGFβ) is an immunosuppressive cytokine produced by tumour cells and immune cells that can polarize many components of the immune system. This Review covers the effects of TGFβ on natural killer (NK) cells, dendritic cells, macrophages, neutrophils, CD8 + and CD4 + effector and regulatory T cells, and NKT cells in animal tumour models and in patients with cancer. Collectively, many recent studies favour the hypothesis that blocking TGFβ-induced signalling in the tumour microenvironment enhances antitumour immunity and may be beneficial for cancer therapy. An overview of the current drugs and reagents available for inhibiting TGFβ-induced signalling and their phase in clinical development is also provided.
As most tumours present self antigens, peripheral tolerance has an important role in contributing to immune evasion by tumours. In addition, the over production of immunosuppressive cytokines, including transforming growth factorβ (TGFβ), by tumour cells and tumourinfiltrating leukocytes also contributes to an immunosuppressive microenvironment. Many stud ies indicate that TGFβ can promote cancer metastasis through effects on the tumour microenvironment by enhancing tumour cell invasion and by inhibiting the function of immune cells 1, 2 . These findings have pro moted interest in targeting TGFβ and its signalling pathway in patients with cancer. However, such target ing of TGFβ could result in adverse effects in normal tissues, as TGFβinduced signalling is also involved in many homeostatic processes (FIG. 1) . For example, TGFβ can function as a tumour suppressor to prevent tumori genesis; however, overproduction of TGFβ is frequently associated with tumour metastasis and poor prognosis in patients with cancer (FIG. 1) . Although the molecu lar mechanisms behind this dichotomy of TGFβ func tions are not fully elucidated, progress has been made in understanding the role of TGFβ in different stages of cancer. This topic has recently been reviewed 1, [3] [4] [5] and is not discussed here.
This Review focuses on the tumourpromoting properties of TGFβ, which prevent effective antitumour immune responses once cancer has been established in the host. A successful immune response requires the proper activation and maturation of antigen presenting cells (APCs) of the innate immune system that present antigen to adaptive immune cells. TGFβ can suppress or alter the activation, maturation and differentiation of both innate and adaptive immune cells, including natural killer (NK) cells, dendritic cells (DCs), macrophages, neutrophils, and CD4 + and CD8 + T cells 6 . A dampened innate immune response leads to poor adaptive immunity, resulting in persistence of the tumour. In addition, TGFβ has an important role in the differentiation and induction of natural and induced regulatory T (T Reg ) cells, which also con tribute to the tolerizing environment. Furthermore, in the presence of interleukin6 (IL6), TGFβ induces the differentiation of IL17producing CD4 + T helper 17 (T H 17) cells and CD8 + cytotoxic T cells; however, the role of IL17producing cells in tumour biology still remains controversial, given that these cells can have both tumourpromoting and antitumour activities 7 . As we discuss, many recent discoveries have been made towards understanding the biological effects of TGFβ on different immune cells, although multiple areas require further investigation. Finally, there is compelling evidence to support targeting TGFβ with inhibitors to enhance antitumour immunity in patients with cancer.
Effects of TGFβ on innate immune cells NK cells. NK cells are innate lymphoid cells that have an important role in the antitumour response by rec ognizing and directly killing primary tumours and metastases to the lungs 8 , as well as rapidly producing chemokines and cytokines crucial for these functions. 
Peripheral tolerance
The lack of responsiveness of mature lymphocytes in the periphery to specific self antigens. These mechanisms can control potentially self-reactive lymphocytes that have escaped central tolerance or prevent immune responses to specialized self proteins that were not present during establishment of central tolerance. Peripheral tolerance is associated with suppression of self-reactive antibody production by B cells and inhibition of self-reactive effector cells, such as T helper cells and cytotoxic T lymphocytes.
Myeloid-derived suppressor cells (MDSCs) . A subset of immature CD11b + GR1 + cells (which include precursors of macrophages, granulocytes, dendritic cells and myeloid cells) that are produced in response to various tumour-derived cytokines. These cells have been shown to induce tumour-associated antigen-specific CD8 + T cell tolerance.
For example, interferonγ (IFNγ) production by NK cells is important for stimulating effector CD4 + T H 1 cells that are required for clearing tumours. TGFβ attenuates IFNγ production by NK cells and their lytic activity 9, 10 . These might be direct effects of TGFβ or might result indirectly from cell-cell contact between NK cells and regulatory T (T Reg ) cells producing this cytokine 11 . In support of a direct effect, TGFβ can suppress IFNγ pro duction through sMAD3, a transcription factor down stream from TGFβinduced signalling, which results in suppression of Tbet, a transcription factor required for IFNγ production 12 . Targeted killing by NK cells requires stimulating the NK cell activating receptors natural killer group 2, member D (NKG2D), NKp46, NKp44 and NKp30 (ReF. 13) . It has been shown that exogenously admin istered TGFβ inhibits NKp30 and NKG2D expression, leading to decreased ability of NK cells to kill target cells 14 . TGFβ also decreases expression of NKG2D by NK cells and CD8 + T cells from patients with glioma who have a high tumour burden 15 . In patients with lung and colorectal cancer, the downregulation of NKG2D expression has been associated with increased serum levels of TGFβ 16 . Furthermore, recent studies of isolated NK cells from healthy donors have shown that platelet derived TGFβ results in downregulation of NKG2D expression, causing a decrease in IFNγ production and of the degranulation functions that are essential for tumour destruction by these cells 17 . Finally, surface bound TGFβ on myeloid-derived suppressor cells (MDsCs) can inhibit NK cell cytolytic activity in an orthotopic liver cancer model 18 . These observations indicate that TGFβ has immunosuppressive effects on NK cell kill ing functions in patients with cancer and, therefore, might be a target for enhancing NK cellmediated antitumour immune responses.
Dendritic cells. DCs are APCs that have a crucial role in the initial activation and subsequent regulation of immune responses 19 . In addition to activating T cell mediated adaptive immunity, DCs can also activate NK cells 20 . DCs can present antigen in an immunogenic or tolerogenic manner, and so they have an important role in determining the host response to tumours 19, 21 . DC activation involves the upregulation of MHC and costimulatory molecule expression, alteration in motility and the formation of dendrites to increase the surface area for antigen presentation and interaction with lymphocytes 22 . Nonactivated or immature DCs can still present antigen but, in the absence of proper costimulation, this results in T cell tolerance 23, 24 . In the presence of immuneinhibiting signals, such as IL10 and/or corticosteroids, DCs can induce tolerance by T cell deletion and/or the activation and induction of T Reg cells 25, 26 . so, DCs can induce either immunity or peripheral tolerance and are an essential determinant of antitumour immunity.
TGFβ affects DC biology in several ways: TGFβ can immobilize DCs, thereby interfering with their migra tion and the transport of antigen to draining lymph nodes for presentation to adaptive immune cells, and it might also directly induce DC apoptosis [27] [28] [29] . Tumour infiltrating DCs both secrete and respond to TGFβ, in either an autocrine or paracrine manner, by down regulating expression of MHC class II molecules and of the costimulatory molecules CD40, CD80 and CD86, and by decreasing production of tumour necrosis fac tor (TNF), IFNα, IL12 and CCchemokine ligand 5 (CCL5) 6, 30 . These immature or tolerogenic DCs promote the formation of T Reg cells that potently inhibit the func tion of other T cells 31, 32 . Activated DCs can also activate both natural and induced T Reg cells [33] [34] [35] [36] ; interestingly, the capacity of DCs to induce both types of T Reg cell is 
Tumour-associated macrophages
(TAMs). An important component of the tumour microenvironment. These cells differentiate from circulating blood monocytes that have infiltrated tumours. They can have positive or negative effects on tumorigenesis (that is, tumour promotion or immunosurveillance, respectively).
M1 macrophage
A classically activated macrophage that is stimulated by Toll-like receptor ligands (such as lipopolysaccharide) and IFNγ and that expresses, among others, inducible nitric-oxide synthase and nitric oxide.
M2 macrophage
An alternatively activated macrophage that is stimulated by IL-4 or IL-13 and that expresses arginase 1, the mannose receptor CD206 and the IL-4 receptor α-chain.
greatly increased by TGFβ and IL10 (ReFS 37, 38) . so, in the context of these immunosuppressive cytokines in the tumour microenvironment, DCs take up tumour cells, become tolerogenic TGFβsecreting cells and promote the induction of tumourspecific T Reg cells in both mice and humans [39] [40] [41] [42] . Therefore, a growing body of evidence indicates that T Reg cells are induced by TGFβ produced by DCs; as T Reg cells are one of the main obstacles to successful antitumour immunity, this indicates that the TGFβ pathway might be targeted to enhance antitumour immunity in patients with cancer.
Macrophages. The mass of most solid tumours is made up of a large number of macrophages and, in general, high numbers of tumour-associated macrophages (TAMs) correlate with poor cancer prognosis; however, depend ing on the type and environment of the tumour, TAMs may also have antitumour activity 43, 44 . 46 . It is not clear whether TGFβ is directly involved in converting TAMs from an M1 to M2 phenotype or whether by produc ing large amounts of TGFβ TAMs may contribute to the general immuno suppressive tumour microenvironment. In skin cancer, TGFβmediated recruitment of macro phages into tumours has an important role in immune escape, as it converts a regressing tumour into a pro gressing tumour 47 . It is suggested that TGFβrecruited TAMs are highly phagocytic and can compete with DC function, thereby markedly decreasing the ability of DCs to present tumour antigens to the adaptive immune system 47 . Interestingly, the M2 phenotype of TAMs is mediated by the inhibitory nuclear factorκB (NFκB) subunit p50 and it is thought that the cytokine milieu of the tumour microenvironment is necessary to maintain the phenotype [48] [49] [50] . During tumour progression, the grad ual inhibition of NFκB activity in TAMs correlates with their switch from an M1 to M2 pheno type 51 . Peritoneal macrophages from tumourbearing hosts produce increased levels of TGFβ, are less differentiated and have deficiencies in inflammatory cytokine production owing to decreased expression of NFκB and CCAAT/enhancer binding protein (C/eBP) transcription factors 52 . In this model, the tumourderived factors TGFβ and prostaglan din e 2 individually and additively downregulate NFκB and C/eBP expression by macrophages. There is also evidence that tumourinfiltrating MDsCs secrete high levels of TGFβ, which upregulates CD206 (a deactivation marker characteristic of M2 macrophages) expression in an autocrine manner 53 . It is unclear how TGFβ pro duction is induced in MDsCs and macrophages, but the mechanism might involve IL13 and glucocorticoids 54, 55 . It is conceivable that the excess amount of TGFβ in the tumour micro environment may contribute to the alter native activation of M2 macrophages by downregulating NFκB expression.
Neutrophils. Neutrophils are shortlived polymor phonuclear leukocytes with potent antimicrobial and inflammatory capacities. Despite their known func tion as professional phagocytes, the role of neutrophils in tumour progression has been controversial and has received little attention compared with that of macro phages. Initial studies characterizing the effect of TGFβ on the control of inflammatory responses showed that it was a potent chemotactic factor for neutrophils, pro moting their migration but not degranulation or acti vation 6 . subsequent studies showed that neutrophil migration could also be indirectly affected by TGFβ through regulating the expression of adhesion mol ecules in the endothelium 56, 57 and that TGFβ could inhibit neutrophil cytotoxicity, suggesting that TGFβ might influence human neutrophil activity in vivo 58 . Recently, the contradictory role of neutrophils in both tumour suppression and tumour promotion by directly or indirectly controlling tumour growth, angiogenesis and metastasis (reviewed in ReF. 59) was reevaluated in terms of the characterization of different types of tumourassociated neutrophil (TAN) with polarized N1 or N2 phenotypes 60 . These polarized populations are similar to those that have been described for macro phages; their phenotypic development is influenced by the microenvironment and seems to be controlled by TGFβ in the tumour proximity. N2 neutrophils are characterized by an expression profile that promotes tumour angiogenesis and metastasis [61] [62] [63] . Depletion of this N2 neutrophil subpopulation in untreated tumour bearing mice was sufficient to inhibit tumour growth, even when CD8 + T cells were absent, highlighting the immunosuppressive potential of N2 cells [60] [61] [62] . under TGFβinhibiting conditions, as well as in response to certain activation signals, neutrophils acquire an anti tumour N1 phenotype that promotes tumour cell death and inhibits tumour growth 59, 60, 64, 65 . The lack of systemic effects on neutrophil polarization during TGFβ neutrali zation experiments indicated that the effect is mainly intratumoral, characterized by increased numbers of N1 TANs that express activating chemokines and cytokines, as well as by changes in endothelial adhesion molecule expression 60 . Interestingly N1 and N2 neutrophils were shown to control the activation status of CD8 + T cells. This interplay seemed to be reciprocal as activated CD8 + T cells could control the activation and migration of neutrophils to the tumour microenvironment as well 66 . Clearly a reevaluation of the role of neutrophils in tumour immunology, as well as characterization of the subpopulation polarized by TGFβ, may be required to design more effective immunotherapies.
Effects of TGFβ on effector T cells CD8
+ T cells. CD8 + T cells are a crucial component of antitumour immunity, as tumour antigenspecific cyto toxic T lymphocytes (CTLs) have an important role in the cytolytic killing of tumour cells. several studies have shown a direct correlation between the frequency of CTLs in tumour infiltrating lymphocytes (TILs) and the overall survival of cohorts of patients with cancer; in particular, a high ratio of intratumoral activated cytotoxic CD8 + T cells to T Reg cells leads to improved prognosis [67] [68] [69] [70] . TGFβinduced signalling in tumour specific CTLs dampens their function and frequency in the tumour 71 , and blocking TGFβinduced signal ling on CD8 + T cells results in more rapid tumour sur veillance and the presence of many more CTLs at the tumour site 72 . The coengagement of the T cell receptor (TCR) and TGFβ receptor has been shown to increase CD103 expression on TILs, which might be required for the activity and retention of CTLs in the tumour micro environment; although the function of this integrin on CTLs is not fully understood 73 . several experimental protocols have been used to render CD8 + T cells unresponsive to TGFβ. In a model where a dominantnegative form of TGFβ receptor II (TGFβRII) is expressed by both CD4 + and CD8 + T cells, a strong antitumour immune response was associated with the proliferation and increased activity of tumour specific CTLs 74, 75 . similarly, when tumourspecific CD8 + T cells are rendered unresponsive to TGFβinduced sig nalling by transduction with a similar TGFβRII domi nantnegative construct before adoptive transfer, these cells infiltrate into tumours, secrete cytokines such as IFNγ and can successfully kill tumour cells 76, 77 .
In some tumour models, systemic blockade of TGFβ, using a monoclonal antibody or kinase inhibitors to block downstream signalling, prevents tumour recurrence by affecting the activity of various cell types, including an increase in the cytotoxic activity of CTLs [78] [79] [80] [81] . However, the inhibition of TGFβ using a monoclonal antibody alone is not always sufficient to promote tumour rejec tion in all animal tumour models. In such models, the combination of a TGFβspecific antibody with a vac cine resulted in a synergistic improvement in the inhi bition of tumour growth that is mediated by increased number and activity of CD8 + T cells [82] [83] [84] . It is speculated that in these models, the source of inhibitory TGFβ is the immune system itself and not the tumour, because the antibodymediated blockade is effective at enhanc ing antitumour immune responses even when antibody is administered with a prophylactic vaccine before injec tion of tumour cells 82 . This effect of TGFβ is consistent with the recent finding that TGFβ is responsible for the apoptosis of shortlived effector CD8 + T cells that com prise more than 90% of the effector pool after immu nization with Listeria monocytogenes 85 . TGFβ promotes the apoptosis of these effector T cells by downregulat ing the expression of B cell lymphoma 2 (BCL2), which opposes the survival function of IL15 on the shortlived effector T cell population 85 . It is possible that blocking TGFβinduced signalling with the neutralizing antibody during administration of the tumour vaccine inhibits the apoptosis of tumourspecific shortlived effector CD8 + T cells and therefore prevents the termination of CTL population expansion.
TGFβmediated inhibition of CTL function dur ing antitumour immunity might be through several mechanisms. TGFβ directly inhibits CTL function by suppressing the expression of several cytolytic genes, including the genes encoding granzyme A, granzyme B, IFNγ and FAs ligand 71 . TGFβ also attenuates the effec tor function of antigenspecific memory CD8 + T cells by inhibiting Tbet expression, resulting in inhibition of IFNγ production 86 . TGFβ might also block TCR signal ling of TILs by upregulating the expression of sPReD1 (sproutyrelated, eVH1 domain containing 1), which is an inhibitor of the RAs-MAPK (mitogenactivated protein kinase) pathway 87 . Interestingly, TGFβ can also influence CD8 + T cellmediated antitumour immunity by inducing IL17 production by CD8 + T cells, although the effect of IL17 on tumour growth versus immune surveillance remains controversial [88] [89] [90] [91] .
CD4
+ T cells. CD4 + T cells are central orchestrators of adaptive immunity; however, their role in antitumour immune responses has largely been overlooked, mainly owing to the lack of MHC class II expression by most forms of solid cancer. TGFβ has been shown to have effects on all subsets of CD4 + effector T cells by control ling the expression of master transcriptional regulators in these cells. TGFβ inhibits Tbet and GATAbinding protein 3 (GATA3) expression (which determine CTL, T H 1 and T H 2 cell differentiation), whereas it promotes fork head box P3 (FoxP3) and retinoic acid receptorrelated orphan receptorγt (RoRγt) expression (which determine T Reg and T H 17 cell differentiation, respectively) (reviewed in ReF. 92) . The role of CD4 + T cells in tumour biology has been classically studied in the context of T Reg cells, which are covered in a separate section of this Review. This sec tion focuses on the specific role of T H cell subpopulations in the control of antitumour immune responses and how TGFβ in the tumour microenvironment could influence the polarization of each subset.
early studies trying to understand the mechanism of tumourinduced immunosuppression identified TGFβ as one of the main inhibitors of immune responses in the tumour microenvironment 93 . Tumourderived TGFβ was shown to inhibit T H 1 cell responses by shifting infil trating T cells towards a T H 2 cell phenotype, and hence TGFβ promoted a less efficient antitumour immune response 94 . However, later studies comparing the effi cacy of T H 1 and T H 2 effector cell subsets in mediating antitumour immunity showed that both T H 1 and T H 2 cells increased the CTLmediated antitumour response, although T H 1 cells secreting IFNγ seemed to be more effective by promoting APC activation 95, 96 . studies using TCRtransgenic mice further support the requirement for CD4 + T cells to activate memory CTLs in vivo 97 , and interestingly show tumour eradication by CD4 + T cells even in cases where tumours were resistant to CD8 + T cellmediated rejection 98 . These findings suggested a potential benefit of T H cells in cancer immunotherapy and started a search for the most effective antitumour CD4 + effector T cell population. Contradictory reports regarding the role of IL17 in cancer have made it difficult to conclude whether or not T cells expressing this cytokine would be beneficial against tumours 99, 100 . Accumulation of T H 17 cells in the tumour microenvironment has been reported in several types of cancer, as well as the expression of IL6, IL1β and TGFβ by tumour cells, which are key cytokines controlling T H 17 cell differentiation and prolifera tion 101, 102 . T H 17polarized tumourspecific CD4 + T cells were shown to be more efficient than T H 1polarized cells in tumour rejection after adoptive transfer, and this efficiency was probably dependent on IFNγ rather than IL17 production 90 111, 112 . In addition, the production of CCL22 by TAMs surrounding tumours might mediate T Reg cell trafficking to the tumour bed through CCR4 (ReF. 113) . Recently, IL23 production in the tumour microenvironment has been implicated in promoting the proliferation of intratumoral T Reg cells, as these cells express IL23R, have evidence of sTAT3 activation (downstream of IL23R) and are decreased in number in tumourbearing animals treated with a blocking antibody specific for IL23R 26 . IL23 may com plement the effects of TGFβ, which also seems to increase the number of intratumoral T Reg cells.
Recently, a new regulatory T cell subtype has been identified that can be induced and expanded in mice bearing orthotopic liver, lung and melanoma tumours 114 . unlike the conventional T Reg cells described above, this regulatory subtype lacks expression of CD25 and FoxP3. Instead, the cells express the IL2R βchain (also known as CD122), IL10, TGFβ1 and the early activation marker CD69 (ReF. 114) . Activation of CD69 with an agonist antibody results in high levels of membranebound TGFβ expression by these cells through the activation of extracellular signalregulated kinase (eRK), and this might contribute to the ability of this regulatory T cell subset to suppress CD4 + T cell proliferation and promote the growth of established tumours 114 . Although these results suggest that another subset of regulatory T cells associated with TGFβ pro duction can suppress the antitumour immune response, the role of these cells in patients with cancer remains to be determined.
TGFβ, in combination with IL2, is required for the conversion of naive T cells to iT Reg cells in vitro 115, 116 . Furthermore, the induction of T Reg cells by TGFβ might be a mechanism by which tumours escape the anti tumour immune response as several tumours can produce TGFβ 124 . In a mouse fibroblast tumour model, this subset of NKT cells can express high levels of IL13, leading to the production of TGFβ by MDsCs, which in turn results in attenuated antitu mour responses by CD8 + effector T cells 78 . However, in a different tumour model, evaluating antibody mediated blockade of TGFβ combined with a peptide vaccine against a lung cancer tumour line, results sug gested that the IL13 pathway, enhanced by type II NKT cells, might not be the mechanism behind the enhanced antitumour activity observed in vaccinated mice 83 . These results suggest a more complex interplay, which is yet to be determined, between TGFβ, type II NKT cells and effector immune cells responsible for the antitumour response.
Summary successful cancer immunotherapy depends on over coming the immunosuppressive milieu in the tumour microenvironment in patients with cancer. TGFβ has a crucial immunosuppressive role in both the innate and the adaptive arms of the immune response (FIGS 2,3) . In terms of the innate immune response, TGFβ inhib its IFNγ production by NK cells causing dampened CD4
+ T H 1 cell responses. It downregulates expression of the activating receptor NKG2D on NK cells result ing in decreased cytolytic activity and overall poor antitumour responses. TGFβ also influences the pres entation of tumour antigens to the adaptive immune system by decreasing DC migration and promoting DC apoptosis in some tumour models. In general, TGFβ inhibits DC maturation and cytokine produc tion, thereby promoting a tolerogenic environment. In addition, TGFβ produced by tolerogenic DCs contrib utes to T Reg cell differentiation. TGFβ can also favour In the presence of TGFβ, dendritic cells acquire a tolerogenic phenotype characterized by decreased migration, maturation and cytokine production and increased apoptosis. They also gain the ability to induce regulatory T (T Reg ) cell differentiation. TGFβ can also convert N1 neutrophils to a N2 phenotype, which is less cytotoxic. Similarly, TGFβ can promote the recruitment of M2 over M1 macrophages and of tumour-associated macrophages (TAMs), and it can decrease cytokine production by these macrophages by inhibiting nuclear factor-κB (NF-κB) activity. (FIG. 3) . This cytokine inhibits the cytotoxic function of tumourspecific CTLs and promotes apoptosis of the shortlived effector CD8 + T cells. TGFβ also controls the differentiation of several key CD4 + T cell subsets in tumour immunology, including T H 1, T H 17 and T Reg cell subpopulations. Importantly, the effect of TGFβ on the differentiation of CD4 + T cells is influenced by the cytokine milieu in the tumour microenvironment, which indicates that modulating the relative abundance of such factors might promote antitumour responses in vivo. It is well documented that both TGFβ and regulatory T cells have key roles in suppressing the antitumour immune response; however, the precise contributions of TGFβ and different regulatory T cell subsets in suppressing effector cell function are still being evaluated (FIG. 4) Given that TGFβ can actively modulate inflammation and tolerance induction in the many ways described above, TGFβ blockade might enhance antitumour immunity through effects on numerous components of the immune response.
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Targeting TGFβ in cancer immunotherapy
The immunosuppressive effects of TGFβ on immune cell subsets leading to dampened antitumour immune responses as described above strongly sup port the development of TGFβ inhibitors to treat patients with cancer. several inhibitors of TGFβ induced signalling, summarized in oligonucleotides (trabedersen (AP12009; Antisense Pharma)), small molecule inhibitors (LY373636 and LY2157299 (both eli Lilly)) and an allogeneic vaccine approach with a tumour cell line transfected with an antisense construct against TGFβ2, belagenpumatucelL (NovaRx Corporation) [128] [129] [130] [131] [132] [133] . The results from these trials evaluating TGFβ block ade alone indicate that inhibitors of TGFβ may enhance antitumour immune responses in patients with cancer. However, further immunological endpoints -includ ing evaluating the effects of TGFβ blockade by these approaches on effector T cell to T Reg cell ratios in the tumour bed, NK cells, NKT cells and MDsCs -have been limited or missing in the most recent studies. For example, peripheral mononuclear cells isolated from patients with highgrade gliomas receiving trabedersen had increased antitumour activity against glioma cells when stimulated with IL2 ex vivo 132 , which indicates that this approach might enhance antitumour responses in patients receiving trabedersen. However, no further immunological characterization of this approach has been published so far. Another example is the evalua tion of the antisense vaccine approach in patients with lung cancer who received belagenpumatucelL. Initial studies reported increased serum levels of IFNγ or immunoglobulins specific for the administered vaccine cells in a cohort of patients enrolled in these trials 130 . However, tumour antigenspecific immune responses, as well as evaluation of the effector and regulatory immune cell compartments, in patients receiving these therapies were not further addressed. In fact, the most recently published Phase II trial with this vaccine lacked immunological endpoint analyses, focusing instead on clinical endpoints for patients with lung cancer strati fied according to different levels of circulating tumour cells 131 . without further characterization of the immu nological effects on patients with cancer receiving antiTGFβ therapies, it may be difficult to interpret the importance of the limited clinical efficacy shown in the most recent trial data. Nevertheless, additional tri als evaluating the small molecule inhibitors, antibody mediated blockade and infusion of CTLs transfected with the dominantnegative TGFβRII are ongo ing, with additional immunological endpoints to be evaluated in the last trial, including CTL survival and function (TABLe 1) .
Although systemic blockade of TGFβ has been well tolerated in preclinical studies, given the pleiotropic effects of this cytokine, one potential concern of this type of therapy is the development of autoimmune toxicities in humans. This could be particularly prob lematic if TGFβ blockade is used in combination with other immuneactivating agents, such as cytotoxic T lymphocyte antigen 4 (CTLA4) or programmed cell death 1 (PD1)specific antibodies (which are also being evaluated as single agents in clinical trials and have shown several autoimmune toxicities) 134 . other poten tial toxicities of blocking TGFβ might result from the cytokine's homeostatic functions in other tissues out side of the immune system, including angiogenesis and the development of musculoskeletal tissues, and TGFβ could also potentially increase the risk of developing new malignancies.
The manipulation of local TGFβ sources in the tumour should be considered in the future as a strategy to inhibit the dominant immunosuppressive intratumoral environ ment while promoting antitumour immunity. Challenges to this approach include being able to target the tumour microenvironment with TGFβ inhibitors without affect ing TGFβ function in the rest of the host to maintain systemic homeostatic processes. This might require new delivery systems, as well as effective TGFβspecific drugs that have minimal systemic toxicities for the recipient.
Future directions
Given that TGFβ affects the activity and differentiation of numerous immune cell types, it is unclear which of the effects of TGFβ is most important in the tumour microenvironment. This is, in part, due to the pleio tropic nature of TGFβ and the contextual and combi natorial effects that this cytokine can have at a range of biological concentrations on different cell types at various stages of their development. Therefore, there remain several questions regarding the basic biology of this cytokine as well as the best strategy to mod ulate this pathway, alone and in combination with other pathways, to enhance antitumour immunity in patients with cancer.
Although it is thought that tumour cells are an impor tant source of TGFβ in the tumour microenvironment, immune cells themselves might in fact produce more of this cytokine, which is produced by effector T cells, regulatory T cells, APCs and MDsCs. Identifying the most relevant source of TGFβ and the exact cells that can respond to this cytokine is important, as localized immunotherapy in the tumour microenvironment might be safer than systemic therapies that could inter fere with the systemic homeostatic functions of TGFβ. In addition, TGFβ is expressed and synthesized as an inactive latent form, which cannot bind to its receptor. TGFβ becomes activated by interacting with molecules such as plasmin, matrix metalloproteinases, reactive oxygen species, thrombospondin 1, αVβ6 integrin and αVβ8 integrin 6, 92 . Notably, the cells that can activate TGFβ may be different from those that produce this potent cytokine, and so this activation step provides a In preclinical studies DNR-transfected EBV-specific CTLs were resistant to antiproliferative effects of exogenously administered TGFβ and had enhanced cytolytic activity in vitro as well as enhanced antitumour activity against EBV-positive lymphomas engrafted in SCID mice 160 . Phase I clinical trials evaluating the safety of this approach in patients with lung cancer and lymphoma are ongoing CTL, cytotoxic T lymphocyte; DC, dendritic cell; DNR, dominant-negative receptor; EBV, Epstein-Barr virus; IFNγ, interferon-γ; MDSC, myeloid-derived suppressor cells; NK, natural killer; polyI:C, polyinosinic-polycytidylic acid; R, receptor; SCID, severe combined immunodeficient; TGFβ, transforming growth factor-β; T Reg , regulatory T. Nature Reviews | Immunology
New targets Trx-lef1 MAPK PI3K RHO-GTPase means for TGFβ to integrate signals from several cell types 92 . we know little about how TGFβ is activated in a tumourbearing environment and whether tolero genic DCs, TAMs or MDsCs have a greater capacity to activate TGFβ than their immunogenic counterparts. Therefore, a precise understanding of the mechanisms by which immunosuppressive cell subsets work alone and together, and their specific involvement in pro ducing and/or activating TGFβ, may improve cancer immunotherapies.
Further studies are also warranted to evaluate the effect of increasing innate and adaptive immune responses in a tumourbearing host. For example, inhibition of TGFβ offers a means to manipulate T cell polarization in vivo that can change an immunosuppressive environment into a more antitumour environment once a tumour has established in the host, as is the case in the treat ment of patients with cancer when these types of thera pies are generally being considered. once the exact role of IL17 and T H 17 cells in antitumour immunity has been defined, modulation of TGFβ levels might also be used to alter the ratio between T Reg cells and T H 17 cells in the tumour microenvironment, as high con centrations of TGFβ may favour T reg cells, whereas low concentrations of TGFβ may lead to T H 17 cell differen tiation 135 . In addition, blocking TGFβinduced signal ling in combination with tumour vaccines promotes antitumour immunity that is mediated, in part, by CD8 + T cells [82] [83] [84] 136 , which could lead to a longterm response with immunological memory.
Additional areas for future research related to the development of agents that efficiently block TGFβ and its activity include pharmacodynamic profiling of tissue TGFβ concentrations and the optimization of strategies to block the most appropriate TGFβdependent signal ling pathways. For example, the blockade of sMAD independent pathways of TGFβdependent signalling, including MAPKs, Rho GTPases and phosphoinositide 3kinases that are involved in tumour progression and metastasis, could lead to new strategies to enhance antitumour immunity (FIG. 5) . Mutations in sMAD2, sMAD3 and sMAD4 lead to cancer progression 137, 138 , indicating that the tumoursuppressor properties of TGFβ involve sMADdependent signalling and, therefore, that sMADdependent pathways may not be ideal therapeutic targets. Future studies analysing the contribution of sMADindependent and sMAD dependent TGFβmediated signalling pathways in controlling antitumour immune responses in addition to their role in tumour parenchymal cells are required. understanding the intricate signalling pathways con trolled by TGFβ, in both tumour and immune cells, as well as the mechanism (or mechanisms) leading to its opposing effects in tumour biology, could lead to new strategies against cancer 139 . Furthermore, identifying the ideal timing of TGFβ blockade in the host, if used in combination with vac cines, cytokine therapies (IL2 and IL15) or other immuneactivating antibodies (such as CTLA4, PD1 or PDL1specific blocking antibodies) would be inform ative 140 . Finally, designing optimal methods to deliver the most effective TGFβ inhibitor to the tumour micro environment and the evaluation of exposing expanded T cell subsets to these drugs ex vivo to enhance adoptive T cellbased immunotherapies are all areas requiring further investigation. so far, the clinical trials evaluating blockade of TGFβ in patients with cancer do not show a clear clin ical benefit. Therefore, larger studies are warranted to clarify the toxicity and efficacy of these strategies. In addition, the optimal dose and timing of TGFβ block ade, as well as the ideal combination of this approach with other immunotherapies, remain unknown. These questions are currently being addressed in ongoing preclinical studies and are likely to be the focus of future clinical trials.
